These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31449815)

  • 1. Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences.
    Crommelin DJA; Mastrobattista E; Hawe A; Hoogendoorn KH; Jiskoot W
    J Pharm Sci; 2020 Jan; 109(1):30-43. PubMed ID: 31449815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars: current scientific and regulatory considerations.
    Chugh PK; Roy V
    Curr Clin Pharmacol; 2014 Feb; 9(1):53-63. PubMed ID: 23952143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assays used to assess biosimilarity of therapies for inflammatory bowel disease.
    Veisman I; Ben-Horin S
    Expert Opin Drug Discov; 2020 Feb; 15(2):139-144. PubMed ID: 31805797
    [No Abstract]   [Full Text] [Related]  

  • 4. Midyear Commentary on Trends in Drug Delivery and Clinical Translational Medicine: Growth in Biosimilar (Complex Injectable Drug Formulation) Products Within Evolving Collaborative Regulatory Interagency (FDA, FTC, and DOJ) Practices and Enforcement.
    Ho RJ
    J Pharm Sci; 2017 Feb; 106(2):471-476. PubMed ID: 27876365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
    Dolinar R; Lavernia F; Edelman S
    Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontiers in nonclinical drug development: biosimilars.
    Ryan AM
    Vet Pathol; 2015 Mar; 52(2):419-26. PubMed ID: 25161206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of biologicals and biosimilars - safety concerns.
    Bonovas S; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):567-569. PubMed ID: 28475378
    [No Abstract]   [Full Text] [Related]  

  • 8. Introduction of a process mass intensity metric for biologics.
    Budzinski K; Blewis M; Dahlin P; D'Aquila D; Esparza J; Gavin J; Ho SV; Hutchens C; Kahn D; Koenig SG; Kottmeier R; Millard J; Snyder M; Stanard B; Sun L
    N Biotechnol; 2019 Mar; 49():37-42. PubMed ID: 30121383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The advent of biosimilars: challenges and risks.
    Müller R; Renner C; Gabay C; Cassata G; Lohri A; Hasler P
    Swiss Med Wkly; 2014; 144():w13980. PubMed ID: 24984255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tracking the price of existing biologics when drugs enter the market.
    Stiff KM; Cline A; Feldman SR
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):375-377. PubMed ID: 31177860
    [No Abstract]   [Full Text] [Related]  

  • 18. Implications of biosimilars for the future.
    Johnson PE
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S16-22. PubMed ID: 18591711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality by design for biopharmaceuticals.
    Rathore AS; Winkle H
    Nat Biotechnol; 2009 Jan; 27(1):26-34. PubMed ID: 19131992
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.